603883.SH
老百姓
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 13.01
−1.44%Year over year
Reported trailing growth
- Revenue
- +0.1%
- EBITDA
- —
- EBIT
- -6.3%
- EPS
- -11.4%
- Free cash flow
- +56.1%
- Operating cash flow
- +32.5%
Forward estimates
Based on analyst estimates
- Revenue
- +10.0%
- EBITDA
- +107.2%
- EPS
- +27.0%
Three-year CAGR
- Revenue
- +3.3%
- EBITDA
- -7.4%
- EBIT
- -15.0%
- Net income
- -21.4%
- EPS
- -28.4%
- Free cash flow
- +12.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026